These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 23369845)

  • 21. Primary antifungal prophylaxis: decrease of invasive fungal disease incidence and reduction of risk factors in haematological patients in a 5-year retrospective study.
    Li Y; Liu M; Zhai B; Zhao X; Wang L; Li H; Wang S; Zhu H; Wang Q; Gao C; Huang W; Yu L
    Intern Med J; 2018 Jun; 48(6):713-720. PubMed ID: 29230923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study.
    León C; Ruiz-Santana S; Saavedra P; Galván B; Blanco A; Castro C; Balasini C; Utande-Vázquez A; González de Molina FJ; Blasco-Navalproto MA; López MJ; Charles PE; Martín E; Hernández-Viera MA;
    Crit Care Med; 2009 May; 37(5):1624-33. PubMed ID: 19325481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Invasive fungal infection in critically ill patients].
    Garnacho-Montero J; Díaz-Martín A; Ruiz-Pérez De Piappón M; García-Cabrera E
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):338-43. PubMed ID: 22503211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Problematic Dichotomization of Risk for Intensive Care Unit (ICU)-Acquired Invasive Candidiasis: Results Using a Risk-Predictive Model to Categorize 3 Levels of Risk From a Multicenter Prospective Cohort of Australian ICU Patients.
    Playford EG; Lipman J; Jones M; Lau AF; Kabir M; Chen SC; Marriott DJ; Seppelt I; Gottlieb T; Cheung W; Iredell JR; McBryde ES; Sorrell TC
    Clin Infect Dis; 2016 Dec; 63(11):1463-1469. PubMed ID: 27601224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-emptive diagnosis and treatment of fungal infections--evaluation of a single-centre policy.
    Schneider T; Halter J; Heim D; Passweg J; Stern M; Tichelli A; Weisser M; Gerull S
    Clin Microbiol Infect; 2012 Feb; 18(2):189-94. PubMed ID: 21729194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia.
    Fung M; Kim J; Marty FM; Schwarzinger M; Koo S
    PLoS One; 2015; 10(11):e0140930. PubMed ID: 26554923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
    Sohn HS; Lee TJ; Kim J; Kim D
    Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.
    Shepherd J; Jones J; Frampton GK; Tanajewski L; Turner D; Price A
    Health Technol Assess; 2008 Jun; 12(28):iii-iv, ix-95. PubMed ID: 18547499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections.
    de Vries R; Daenen S; Tolley K; Glasmacher A; Prentice A; Howells S; Christopherson H; de Jong-van den Berg LT; Postma MJ
    Pharmacoeconomics; 2008; 26(1):75-90. PubMed ID: 18088160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Failure of empirical systemic antifungal therapy in mechanically ventilated critically ill patients.
    Bailly S; Bouadma L; Azoulay E; Orgeas MG; Adrie C; Souweine B; Schwebel C; Maubon D; Hamidfar-Roy R; Darmon M; Wolff M; Cornet M; Timsit JF
    Am J Respir Crit Care Med; 2015 May; 191(10):1139-46. PubMed ID: 25780856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Risk Prediction Model for Invasive Fungal Disease in Critically Ill Patients in the Intensive Care Unit.
    Li F; Zhou M; Zou Z; Li W; Huang C; He Z
    Asian Nurs Res (Korean Soc Nurs Sci); 2018 Dec; 12(4):299-303. PubMed ID: 30472388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Common invasive fungal diseases: an overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia.
    Schmiedel Y; Zimmerli S
    Swiss Med Wkly; 2016; 146():w14281. PubMed ID: 26901377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Posaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts.
    Lyseng-Williamson KA
    Pharmacoeconomics; 2011 Mar; 29(3):251-68. PubMed ID: 21309616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ÉPICO project. Development of educational recommendations using the DELPHI technique on invasive candidiasis in non-neutropenic critically ill adult patients.
    Zaragoza R; Llinares P; Maseda E; Ferrer R; Rodríguez A;
    Rev Esp Anestesiol Reanim; 2013; 60(7):e1-e18. PubMed ID: 23911095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
    Schonfeld W; Wang Cheng J; Tong KB; Seifeldin R
    Clin Ther; 2008 May; 30(5):964-73. PubMed ID: 18555943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis.
    Soares MO; Welton NJ; Harrison DA; Peura P; Shankar- Hari M; Harvey SE; Madan JJ; Ades AE; Palmer SJ; Rowan KM
    Health Technol Assess; 2012; 16(7):1-186. PubMed ID: 22361003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Posaconazole prophylaxis--impact on incidence of invasive fungal disease and antifungal treatment in haematological patients.
    Peterson L; Ostermann J; Rieger H; Ostermann H; Rieger CT
    Mycoses; 2013 Nov; 56(6):651-8. PubMed ID: 23710592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain.
    Grau S; de la Cámara R; Sabater FJ; Jarque I; Carreras E; Casado MA; Sanz MA
    BMC Infect Dis; 2012 Apr; 12():83. PubMed ID: 22471553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicentre, randomised controlled trial comparing the clinical effectiveness and cost-effectiveness of early nutritional support via the parenteral versus the enteral route in critically ill patients (CALORIES).
    Harvey SE; Parrott F; Harrison DA; Sadique MZ; Grieve RD; Canter RR; McLennan BK; Tan JC; Bear DE; Segaran E; Beale R; Bellingan G; Leonard R; Mythen MG; Rowan KM
    Health Technol Assess; 2016 Apr; 20(28):1-144. PubMed ID: 27089843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature.
    Dixon S; McKeen E; Tabberer M; Paisley S
    Pharmacoeconomics; 2004; 22(7):421-33. PubMed ID: 15137881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.